JacobDBitranMD

Oncology • Park Ridge, IL

Oncology Specialists

Join to view full profile

Dr. Bitran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Bitran's full profile

Already have an account?

Office
1775 Dempster St
Park Ridge, IL 60068
Phone+1 847-723-2210

Fax+1 847-723-6667
Is this information wrong?

Summary

Dr. Jacob Bitran is an oncologist in Park Ridge, IL and is affiliated with Advocate Lutheran General Hospital. He received his medical degree from University of Illinois College of Medicine and has been in practice 46 years. He specializes in hematologic oncology and is experienced in hematologic oncology and lymphoma & myeloma.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1977
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1975
Rush University Medical CenterResidency, Pathology-Anatomic and Clinical, 1972 - 1973
Michael Reese Hospital and Medical CenterInternship, Internal Medicine, 1971 - 1972
University of Illinois College of MedicineClass of 1971

Certifications & Licensure

CA State Medical License 1976 - Present
IL State Medical License 1972 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Chicago Magazine: Top Doctors Castle Connolly, 2004, 2006, 2008, 2010, 2012, 2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Whos Who in Medicine and Healthcare Marquis Whos Who
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis Start of enrollment: 2013 Oct 01
Withdrawn
Not Applicable
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2014 Mar 08
Completed
Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

A Case of Recurrent Multiple Myeloma as Testicular Plasmacytoma Without Systemic Disease.
Krishna Doshi, Sabree Abedrabo, Jacob Bitran, Nahren Asado> ;Cureus. 2023 Jun 1
Mantle Zone Lymphoma With Prostate Gland Enlargement: A Case Report.
Krishna Doshi, Anjana Chandran, Yanxia Li, Jacob Bitran> ;Cureus. 2022 Nov 1
13 citations
A Review of the Abscopal Effect in the Era of Immunotherapy.
Edward Nabrinsky, Jason Macklis, Jacob Bitran> ;Cureus. 2022 Sep 1
Immunoglobulin Light Chain (AL) Amyloidosis Preceding Marginal Zone Lymphoma: A Case Report.
Krishna Doshi, Jacob Bitran, Brian Adley, Nahren Asado> ;Cureus. 2022 Jul 1
1 citations
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezo...
David Daniely, Eli Forouzan, Tanya M Spektor, Alexa Cohen, Jacob D Bitran, Gigi Chen, Mehdi M Moezi, Alberto Bessudo, John Hrom, Shahrooz Eshaghian, Regina A Swift, Be...> ;Experimental Hematology. 2022 Jul 1
Primary Central Nervous System Lymphoma With Systemic Recurrence.
Sasirekha Pandravada, Phillip Knouse, Jacob D. Bitran> ;Cureus. 2021 Sep 30
Therapy-Related Acute Myeloid Leukemia Following TCHP Chemotherapy in Two HER2+ Breast Cancer Patients.
Navroop Gill, Anjana Chandran, Brian Adley, Jacob Bitran> ;Cureus. 2020 Dec 7
DA-REPOCH Versus R-CHOP for the Treatment of Activated B-Cell Subtype Diffuse Large B-Cell Lymphoma: A Community Center Experience.
Phillip Knouse, Edward Nabrinsky, Ronald Sirota, David Hakimian, Jacob D. Bitran> ;Cureus. 2020 Nov 26
5 citations
Reducing Unwarranted Oncology Care Variation Across a Clinically Integrated Network: A Collaborative Physician Engagement Strategy
Jon M Richards, Trever Burgon, Diana Tamondong-Lachica, Jacob D Bitran, Wilfredo L. Liangco, David Paculdo, John W. Peabody> ;Journal of Oncology Practice. 2019 Oct 1
156 citations
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson, Anupkumar George, Hartmut Goldschmidt, Alessandra Larocca, Asher Chanan-Khan,...> ;The Lancet. Haematology. 2019 Jul 18
14 citations
The Abscopal Effect Exists in Non-small Cell Lung Cancer: A Case Report and Review of the Literature.
Jacob D. Bitran> ;Cureus. 2019 Feb 22
2 citations
An Attempt to Quantitate "Value" In Medical Oncologic Therapy.
Christie Hancock, Linda Green, Timothy M. Lestingi, Jacob D. Bitran> ;Cureus. 2018 Jun 14
2 citations
A Retrospective Study of Double-hit Lymphomas in Elderly Patients (Aged > 70 Years): Overall Outcomes.
Christie Hancock, Phillip Knouse, Imad Almanaseer, Jacob D. Bitran> ;Clinical Lymphoma, Myeloma & Leukemia. 2018 Apr 1
2 citations
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Aleksandra Vidisheva, James Wang, Tanya M. Spektor, Jacob D. Bitran, Jose Lutzky, Imad A. Tabbara, Joseph Z. Ye, Sikander Ailawadhi, Laura Stampleman, Ronald G. Steis,...> ;Supportive Care in Cancer. 2017 Apr 28
12 citations
Role of Sorafenib in Overcoming Resistance of Chemotherapy-Failure Castration-Resistant Prostate Cancer
Andrew Meyer, Peter Cygan, Kathy Tolzien, Angel G. Galvez, Jacob D. Bitran, Timothy M. Lestingi, Chadi Nabhan> ;Clinical Genitourinary Cancer. 2014 Apr 1
15 citations
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostat...
Chadi Nabhan, Dana Villines, Tina V. Valdez, Kathy Tolzien, Timothy M. Lestingi, Jacob D. Bitran, Susan M. Christner, Merrill J. Egorin, Jan H. Beumer> ;British Journal of Cancer. 2012 Aug 7
Overcoming chemotherapy resistance in patients (pts) with chemotherapy-failure, castration-resistant prostate cancer (CRPC) with sorafenib.
Nabhan C, Cygan PH, Meyer A, Tolzien K, Galvez AG, Lestingi TM, Bitran JD> ;J. Clin. Oncol.. 2012-02-10
Phase I study of imatinib mesylate (IM) and sorafenib (S) in patients (pts) with refractory castration-resistant prostate cancer (CRPC).
Nabhan C, Villines D, Valdez TV, Tolzien K, Lestingi TM, Bitran JD, Susan CM, Egorin MJ, Beumer JH> ;J. Clin. Oncol.. 2012-02-10
A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration -...
Chadi Nabhan, Andrew Meyer, Kathy Tolzien, Jacob D. Bitran, Timothy M. Lestingi> ;Avicenna Journal of Medicine. 2011 Jul 1
13 citations
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
Chadi Nabhan, Nancy Davis, Jacob D. Bitran, Angel G. Galvez, Walter Fried, Kathy Tolzien, Susan Foss, Wendy M. Dewey, Parameswaran Venugopal> ;Cancer. 2011 Apr 1
2 citations
Disclosing the Cancer Diagnosis:The Myth and the Truth
Chadi Nabhan, Jacob D. Bitran, Clint Moore> ;Journal of Clinical Oncology. 2011 Feb 20
Efficacy and safety of clofarabine in relapsed and/or refractory non-hodgkin lymphoma, including rituximab-refractory patients.
Nabhan, C., Davis, N., Bitran, J.D., Galvez, A., Fried, W., Tolzien, K., Foss, S., Dewey, W.M., Venugopal, P.> ;Cancer. 2010-11-08
3 citations
Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?
Chadi Nabhan, A Ragam, Jacob D. Bitran, Jayesh Mehta> ;Bone Marrow Transplantation. 2010 Apr 12
58 citations
A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR
Hillard M. Lazarus, Mei-Jie Zhang, Jeanette Carreras, Brandon Hayes-Lattin, Asli Selmin Ataergin, Jacob D. Bitran, Brian J. Bolwell, Cesar O. Freytes, Robert Peter Gal...> ;Biology of Blood and Marrow Transplantation. 2010 Jan 1
36 citations
Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial
Chadi Nabhan, Timothy M. Lestingi, Angel G. Galvez, Kathy Tolzien, Susan K. Kelby, Dean Tsarwhas, Steven Newman, Jacob D. Bitran> ;Urology. 2009 Sep 1
Join now to see all

Authored Content

A Retrospective Study of Double-Hit Lymphomas in Elderly Patients (> 70 Years): Overall OutcomesFebruary 2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Advocate Lutheran General HospitalPark Ridge, Illinois
Advocate Illinois Masonic Medical CenterChicago, Illinois